Universitätsklinikum Erlangen

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas

  NCT07888647· Phase 2· German Cancer Research Center· Source

• Not yet recruiting

  HIIT-based Exercise Intervention for Improvement of Immunomodulatory, Cardiopulmonary, and Psychosocial Parameters During Maintenance Therapy of Paediatric Acute Lymphoblastic Leukaemia (HEALL)

  NCT07936786· University of Erlangen-Nürnberg Medical School· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· German Cancer Research Center· Source

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  SIL204-SL Treatment for Locally Advanced Pancreatic Cancer

  2025-525157-39-00· Phase 2/3· Silexion Therapeutics Ltd.· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Exercise and Fall Prevention for Fracture Reduction

  NCT07897929· Wolfgang Kemmler, PhD· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· Phase 2· Universitair Medisch Centrum Groningen· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

  NCT07775924· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).

  2025-523971-46-00· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine

  NCT07661940· Phase 2· University of Erlangen-Nürnberg Medical School· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Not yet recruiting

  Study of Zola-cel (BMS-986353), CD19 NEX-T CAR T Cells in Autoimmune Cytopenia (Breakfree-AiCE)

  2025-524993-41-00· Phase 2· Celgene Corp.· Source

• Not yet recruiting

  Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

  NCT07553650· Charite University, Berlin, Germany· Source

• Recruiting

  Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

  NCT07649681· Wuerzburg University Hospital· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Dr. Andreas Ziegler· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· AstraZeneca· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

  2025-521390-14-00· Phase 2· Pediatric Research International GmbH· Source

• Recruiting

  Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.

  2025-522138-29-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· University Of Cologne· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Multicenter Study for External Validation of the TB-NET Score

  NCT07903532· Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz· Source

• Not yet recruiting

  A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

  2025-524435-39-00· Phase 2· Charite Universitaetsmedizin Berlin KöR· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons

  NCT07788729· University of Regensburg· Source

• Recruiting

  A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

  2025-523079-44-00· Phase 3· Ascendis Pharma Endocrinology Division A/S· Source

• Recruiting

  Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.

  NCT07561255· Wuerzburg University Hospital· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Quell Therapeutics Limited· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Philipps University Marburg· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study

  2025-522338-30-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

Showing 50 of 310.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers34 recruiting
• Metastatic breast cancer13 recruiting
• Acute lymphoblastic leukaemia11 recruiting
• Melanoma10 recruiting
• Head and neck cancer9 recruiting
• Chronic kidney disease8 recruiting
• Dermatomyositis and polymyositis (myositis)7 recruiting
• Rheumatoid arthritis7 recruiting
• Sarcoma7 recruiting
• Stroke7 recruiting
• Acute myeloid leukaemia6 recruiting
• Colorectal cancer6 recruiting
• Crohn's disease6 recruiting
• Lung cancer6 recruiting
• Systemic sclerosis (scleroderma)6 recruiting
• Triple-negative breast cancer6 recruiting
• Ulcerative colitis6 recruiting
• Gastric and oesophageal cancer5 recruiting
• Immune thrombocytopenia (ITP)5 recruiting
• Lupus (SLE)5 recruiting
• Multiple myeloma5 recruiting
• Neuroendocrine tumours5 recruiting
• Psoriatic arthritis5 recruiting
• Bladder cancer4 recruiting
• Coronary artery disease4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• High blood pressure4 recruiting
• Huntington's disease4 recruiting
• Neuroblastoma4 recruiting
• Parkinson disease4 recruiting
• Antiphospholipid syndrome3 recruiting
• Atrial fibrillation3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Obesity3 recruiting
• Ovarian cancer3 recruiting
• Prostate cancer3 recruiting
• Type 2 diabetes3 recruiting
• Ankylosing spondylitis2 recruiting
• Cervical cancer2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Coeliac disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Follicular lymphoma2 recruiting
• Heart failure2 recruiting
• Hidradenitis suppurativa2 recruiting
• Hodgkin lymphoma2 recruiting
• Kidney cancer2 recruiting
• Lichen planus2 recruiting
• Liver and biliary tract cancer2 recruiting
• Pancreatic cancer2 recruiting
• Psoriasis2 recruiting
• Sjögren's disease2 recruiting
• Alopecia areata1 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Brain metastases1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometrial cancer1 recruiting
• Eosinophilic oesophagitis1 recruiting
• Epilepsy1 recruiting
• Glioblastoma1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Nephrotic syndrome1 recruiting
• Osteoarthritis1 recruiting
• Osteoporosis1 recruiting
• Polycystic ovary syndrome1 recruiting
• Turner syndrome1 recruiting
• Vascular dementia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· Phase 1/2· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Hoffmann-La Roche· Source

• Completed

  Dance Movement Therapy for Radio-oncological Patients

  NCT07001033· University of Erlangen-Nürnberg Medical School· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3

  NCT04524208· Phase 2· Universitaetsmedizin Goettingen· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Alumis Inc· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Janssen Cilag International· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  Rapid pain control in Ixekizumab targeted axial spondyloarthritis

  2023-508976-12-00· Phase 4· Universitaetsklinikum Erlangen AöR· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  MSOT_PI Analysis of Revascularization Procedure Using Optoacoustic Imaging

  NCT06966297· University Hospital Erlangen· Source

• Active, not recruiting

  A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

  NCT06018337· Phase 3· DualityBio Inc.· Source

• Completed

  Finerenone and renal oxidative stress

  2023-508266-15-00· Phase 3· Universitaetsklinikum Erlangen AöR· Source

• Completed

  Early Detection of Fabry Disease

  NCT05106764· Takeda· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

  NCT05870579· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin

  NCT06521190· Phase 2· Acousia Therapeutics GmbH· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Almirall S.A.· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

  2022-502040-13-00· Phase 2· University of Leipzig· Source

• Completed

  Inhibition of JAK enzymes in early stage joint inflammation

  2024-514026-23-00· Phase 2· Universitaetsklinikum Erlangen AöR· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

  NCT05938725· Phase 1/2· Kyverna Therapeutics Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Berlin Cures GmbH· Source

• Completed

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· Phase 3· Amgen Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

  NCT05627557· Phase 3· Hoffmann-La Roche· Source

• Completed

  An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)

  2022-501850-12-00· Phase 2· Arctic Bioscience AS· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT05620836· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Terminated

  KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

  NCT06342960· Phase 1/2· Kyverna Therapeutics· Source

• Completed

  Post Market Clinical Follow-up Study for the Pamira ICD Lead Family

  NCT05621187· Biotronik SE & Co. KG· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· Phase 1· Genmab· Source

• Completed

  Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

  NCT05380453· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A DELETERIOUS GERMLINE MUTATION IN BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 OR A HOMOLOGOUS RECOMBINATION DEFICIENCY

  NCT05033756· Phase 2· Institut fuer Frauengesundheit GmbH· Source

Showing 50 of 104.

Conditions

Diseases this institution publishes on or runs trials for.

• Ulcerative colitis48 works · 16 trials
• Glioblastoma48 works · 1 trial
• Epilepsy43 works · 3 trials
• Melanoma43 works · 18 trials
• Rheumatoid arthritis35 works · 9 trials
• Systemic sclerosis (scleroderma)35 works · 11 trials
• Psoriasis33 works · 11 trials
• Crohn's disease30 works · 11 trials
• Bladder cancer28 works · 8 trials
• Lupus (SLE)27 works · 12 trials
• Sarcoma21 works · 6 trials
• Psoriatic arthritis19 works · 9 trials
• Metastatic breast cancer18 works · 33 trials
• Brain metastases14 works · 2 trials
• Neuroendocrine tumours12 works · 11 trials
• Cytomegalovirus infection9 works · 0 trials
• Chronic myeloid leukaemia8 works · 6 trials
• Alopecia areata7 works · 3 trials
• Duchenne muscular dystrophy6 works · 2 trials
• Vitiligo5 works · 6 trials
• Lichen planus4 works · 2 trials
• Polycystic kidney disease4 works · 0 trials
• Multiple system atrophy3 works · 1 trial